CLINICAL_TRIALS
trial_result
· 2025-12-12
Clinical Trial Update: Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab [Phase 3]
Summary
A Phase 3 trial evaluating adjuvant avelumab for high-risk triple-negative breast cancer has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Istituto Oncologico Veneto IRCCS | Conditions: Triple Negative Breast Neoplasms | Phase 3 | Status: COMPLETED